French Authorities Approve Phase III Clinical Trial for Ovarian Cancer Chemotherapy Adjustment

Paris, May 7, 2024 – The French Competent Authorities have given their final approval for the SALVOVAR study, a pragmatic Phase III randomized trial. This study aims to evaluate the effectiveness of adjusting the dose and administration schedule of chemotherapy for ovarian cancer patients whose prognosis is poor due to tumor chemosensitivity and incomplete surgical resection.

In France, agreements are currently under review in about ten centers and will soon be dispatched to the following institutions. Initial setup meetings (MEP) are scheduled from June to September. The first patient enrollment is anticipated to begin in June 2024.

Internationally, the submission package has been sent to the other participating countries. The inclusion of these countries in the Clinical Trials Information System (CTIS) is planned for June.

This approval marks a significant step forward in addressing the needs of ovarian cancer patients with challenging prognoses and demonstrates a commitment to advancing cancer treatment through rigorous clinical research.